TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • Sustainability
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > Chemical Characterisation – no simple matter

Chemical Characterisation – no simple matter

Chemical Molecules

Author: James Morrison

Understanding Chemistry is now mandatory

The most recent edition of ISO 10993-1 in 2018 added to the evaluation table (Table A.1) the interesting item “Physical and/or chemical information.” This is interesting for several reasons, not the least of which is that it appears in the list of: “Endpoints for Biological evaluation.” Clearly, it isn’t a biological endpoint, but it appears to be of sufficient importance or significance that it is required (or at least to be “addressed”) for every type of device requiring biological evaluation, regardless of contact type or duration.

Updated standards on chemical and physical assessment

In January 2020, the new edition of ISO 10993-18 on Chemical Characterisation was published offering a very comprehensive (if sometimes intimidating) array of guidance on means and methods for the task.

Then in March 2020, the new edition of ISO/TS 10993-19 on Physiochemical, morphological, and topographical characterisation was published, almost unnoticed. As a Technical Specification, Part 19 is informative only (i.e. contains no formal requirements) and therefore carries less weight than a standard. It is really aimed at the cases where the physical nature of the material (e.g. surface characteristics, porosity) have a significant effect on biological response and so is less frequently used.

Recently, ISO/TC 194/WG 11 Allowable Limits (the ISO group responsible) met again (electronically, in these uncertain times) to continue the revision process for ISO 10993-17. The revision will probably have a new title: Toxicological risk assessment of medical device chemical constituents. The process is now in the “Committee Draft” stage.

Chemistry vs Biology – the drivers of change

But before we get to that interesting event, it’s instructive to review exactly what is going on with biocompatibility, and why all these things are happening.

Biocompatibility is both a physical and a chemical issue. As always with biocompatibility: “Context is King!” The physical aspects seem to be more pertinent to implant devices and those contacting circulating blood. The chemical aspects are more universally applicable. Physical properties are often overlooked. Chemical issues are often ill-understood. This combination, along with the extensive historical precedent, has led us to excessive dependence on animal testing.

Since 1992 we have had the guidance of ISO 10993-2 Animal Welfare Requirements. The drive to replace, reduce and refine animal testing is a big factor in the field of biocompatibility. And these days the emphasis is strongly on replacement. This is obvious in the cosmetics industry, where animal testing has essentially been outlawed. Reduction in animal testing is continuing in biocompatibility, for example, the new ISO 10993-23 Tests for Irritation due to be published early 2021 will include a validated in vitro (cell culture) irritation assay as an alternative to the current animal tests.

In addition to the drive to reduce animal testing, it’s also the case that in some ways, chemical analysis can be scientifically more informative than biological testing. As modern chemical techniques become more and more sensitive, it’s becoming apparent that the detailed information available from chemical analysis can be more sensitive than the biological assays on which biocompatibility has relied for decades. (See more discussion here) This is particularly the case in the analysis of genotoxicity – where chemical analysis can quantify the presence of genotoxic substances. If the chemical analysis rules out the presence of genotoxins, there should be no need for biological testing. Conversely, chemical analysis can sometimes detect the presence of genotoxins which are missed in biological assays, such as Ames testing.

Given the impetus to minimise animal testing and the new opportunities presented by modern chemical analysis, there is an increased interest in (if not dependence on) chemical characterisation. The characterisation data provides the input to Toxicological Risk Assessment of the medical device which can be used to address a number of the (strictly) biological endpoints of Table A.1. Specifically, it is now widely accepted that this approach is valid for Systemic Toxicity (acute, sub-acute, sub-chronic & chronic), Genotoxicity and Carcinogenicity. These are all systemic endpoints driven by availability (exposure dose) of toxic substances leaching from the device and distributed systemically. Local endpoints are not suitable for evaluation in this way.

Interestingly, Material Mediated Pyrogenicity, which is a systemic effect, is not considered to be adequately addressed in this way. In the absence of a validated in vitro method, its evaluation remains an in vivo test (USP, EU or JP rabbit pyrogen test, as per ISO 10993-11 Annex G.)

Finally, don’t underestimate the importance of having methods that are validated. Equally don’t underestimate the complexity and effort involved in such validations. Method validation is a big-ticket item for many ISO Working Groups.

Expect Reviewers to be Conservative

The very broad and informative reach of the revised Part 18 provides excellent guidance, without being too prescriptive. This is helpful and appropriate as a wide range of materials used in medical devices, and the wide range of clinical uses demand a flexible approach where scientific judgment is used to determine what is important for a specific medical device and the most appropriate approach to the assessment of chemical composition. Unfortunately, the same lack of detailed prescription and reliance on expert judgement can lead to divergent interpretations and expectations between manufacturers, laboratories and regulatory reviewers. Thus, manufacturers can be greatly surprised (and disturbed) by a reviewer’s request for additional information. Particularly when the manufacturer believes they are compliant with the standard, but the reviewer takes a different (usually more conservative) view.

The conservative technical expectations of reviewers are normal – it’s their job, and we all have to deal with it. It isn’t going away soon.

The following are some strategies to help you navigate your way through chemical characterisation:

  • Talk to the regulator – as always, a pre-submission before you do anything which involves spending a substantial amount of money is a very good investment. Be careful to succinctly describe the device and what you intend to do and ask just a few carefully considered questions. And of course, be prepared to follow whatever advice the regulator gives you!
  • Collaborate internally – I’m aware that biocompatibility is sometimes the domain of a manufacturer’s Regulatory Affairs department. But in the case of chemical characterisation, everyone is going to have to work together, applying their expertise:
    • Clinical Affairs – how and by whom is the device used.
    • Design Engineers – what parts of the device need to be evaluated.
    • Materials Scientists – (Shameless plug on my part) what is in that material in the first place.
    • Manufacturing Engineers – what might contaminate the device during the various production processes, including residual sterilant.
  • Collaborate externally – Answer as many questions as possible by information “gathering” rather than “generation.” Engage with your supply chain, analytical chemistry labs, and toxicologist to set up whatever testing you do to be most effective and profitable. (no one-size-fits-all solution)
  • Explain and defend every technical consideration in a very clear fashion. “Scientific rationale shall be presented and justified” is the essential mantra.

Part 17 Toxicological Risk Assessment Revision Underway

Working Group 11 recently reviewed approximately 400 comments (possibly unprecedented) on CD 10993-17.

In these unusual times, this was dealt with by a global web meeting extended over 2 weeks, approximately 3 to 4 hours each day. (Somewhat burdensome for those delegates attending in the middle of their night. Such are the wages of “expertise!”)

Half of the comments were from the USA. The rest were from a distributed range of participating countries. Clearly not all 400 comments were individually addressed. There were many duplicate ideas, themes and suggestions, allowing for a reduced number of discussion points, whilst still doing justice to the original comments.

The overall thrust of the comments was technical accuracy and usability of the new revision. It looks like the new version will be much bigger than the current one. It will describe a lot of new applications of toxicology to the field of medical devices, where there has been historically much less interest/use (than say agriculture.) It will help toxicologists and non-toxicologists alike to prepare Toxicological Risk Assessments that are thoroughly scientific and significant in regulatory and safety terms.

And, like chemical characterisation, I’m sure that Toxicological Risk Assessment of medical devices requires and benefits from cross-functional collaboration, good science, and effective communication.

We tailor our services to the requirements of your business and can help you implement plans that are best suited to your projects. 

Contact us
Related posts
IPD strategy seen as key to supporting decision-making, PharmaLex survey finds
IPD strategy seen as key to supporting decision-making, PharmaLex survey finds
11th August 2022
CONSIDERATIONS FOR A VALUE-ADDED INTERNAL AUDIT PROGRAM
CONSIDERATIONS FOR A VALUE-ADDED INTERNAL AUDIT PROGRAM
28th July 2022
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Recent Blogs
  • IPD strategy seen as key to supporting decision-making, PharmaLex survey finds
    11th August 2022
  • CONSIDERATIONS FOR A VALUE-ADDED INTERNAL AUDIT PROGRAM
    28th July 2022
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Events

September 11 - 13th, 2022

2022 RAPS Convergence, Phoenix, USA – 11 to 13 September 2022

Visit us at booth 507

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
pharmalexglobal PharmaLex @pharmalexglobal ·
11 Aug

A Case Study in global End-to-End HQ #Outsourcing: ➡  Download the case study to discover more details: https://lnkd.in/ex_-jpxP

#pharmaindustry

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • We really appreciate your responsiveness and availability during our previous exchanges and it is what we are waiting for from our partner.

    Small Medium Sized Company, UK
    Head of Regulatory Affairs
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for